louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00426374: Assessment of Asymptomatic Heart Disease in Children With HIV
Official title: Evaluation of the Cardiac Complications in Congenitally HIV-1 Infected Children in Israel by the Echocardiography and Measurement of N-Terminal Pro-B-Type Natriuretic Peptide (N-BNP).
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: HIV Infections
Keywords: HIV
AIDS
Troponin
natriuretic peptide
heart failure
heart disease children
HIV pediatric
AIDS pediatric
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2007-01-24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to perform cardiac evaluation in HIV-1 (predominantly clade C)infected children by history, physical examination, echocardiogram and plasma N-terminal pro-B-type natriuretic peptide (N-BNP)measurement in order to determine asymptomatic abnormalities.

Detailed description: Human immunodeficiency virus (HIV) infection affects nearly 40 million adults and children worldwide. Recently introduced new antiviral drugs have significantly improved survival of patients with HIV infection. As mortality declines, morbidity becomes a concern. Heart disease is present in 20% of children and adults with HIV. The cardiac diseases include left ventricular dysfunction, hypertrophy and dilation, pericardial effusion and intracardiac masses. Cardiac disease is an independent risk factor for death in these children. The reported two-year survival of children with congestive heart failure is zero compared to 17% when no heart failure is present. It is thus indicated to perform periodic cardiac examinations in these patients, and early recognition of cardiac disease is paramount.

In addition to the traditional tools to assess cardiac status which include history, physical examination, ECG, chest X-ray and echocardiography, we propose to check biochemical markers. Brain natriuretic peptide has been shown to be a very sensitive marker for symptomatic and asymptomatic cardiac dysfunction, prognosis, severity of the disease and response to therapy in adults. Troponin-T is a very good marker for cardiac ischemia. Recently, we have found troponin-T to be a good marker for acute cardiac insult in infants and children.

The aim of this study is to perform screening of children with HIV predominantly clade C for cardiac disease using the above mentioned means.

Eligibility criteria: Inclusion Criteria:

* Infants and children congenitally infected with HIV-1

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah University Hospital, Pediatric Department, Pediatric AIDS Center
Study officials:
affiliation: Hadassah University Hospital, Jerusalem, Israel
name: Diana Averbuch, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Keesler MJ, Fisher SD, Lipshultz SE. Cardiac manifestations of HIV infection in infants and children. Ann N Y Acad Sci. 2001 Nov;946:169-78. doi: 10.1111/j.1749-6632.2001.tb03911.x.
Clinical trial NCT05571774: Construction of a Database for TTP
Official title: Construction of a Database for Thrombotic Thrombocytopenic Purpura
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: TTP - Thrombotic Thrombocytopenic Purpura
Lead sponsor: The First Affiliated Hospital of Soochow University
Sponsor class: OTHER
First posted: 2022-10-07
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 500 eligible TTP patients are to be collected for this project.

Brief summary: Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software. The sample size is expected to be 200 cases, the participating hospital is the First Affiliated Hospital of Soochow University, and the study time frame is from Oct 20, 2022, to Oct 20, 2027. The observation indexes of the study include the basic information of patients' age and gender and the clinical related data of thrombotic thrombocytopenic purpura.


Eligibility criteria: Inclusion Criteria:

- Subjects diagnosed with severe ADAMTS13 deficiency, defined as ADAMTS13 activity \<10%, documented in the patient's medical history or at screening.

Exclusion Criteria:

- The investigator considers the subject unable or unwilling to cooperate with the study procedures.

Primary outcomes:
measure: Number of participants with stroke
timeFrame: 5 years from the time of entering the database.
Secondary outcomes:
Other outcomes:
Locations:
city: Suzhou
country: China
facility: the first affiliated hospital of Soochow university
state: Jiangsu
Study officials:
References:
Clinical trial NCT02173574: Two-way Interaction Between Alisporivir and EDP239
Official title: An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatitis C Virus
Keywords: Hepatitis C Virus, Viral, Antiviral, Infection, Infectious disease, alisporivir, EDP239, DEB025
Lead sponsor: Enanta Pharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2014-06-25
Enrollment: 42
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of Part 1 is to inform dose selection for use of alisporivir and EDP239 in combination and obtain initial safety data for co-administration of alisporivir and EDP239 to support future treatment studies in patients. The purpose of Part 2 is to inform the drug-drug interaction potential of EDP239 more broadly and possibly facilitate the interpretation of lower than expected alisporivir concentrations in Part 1, if observed.


Eligibility criteria: Inclusion Criteria:

* Male or female subjects 18 to 55 years of age
* Body weight at least 50 kg

Exclusion Criteria:

* Women of child bearing potential
* Tobacco use
* History or evidence of any inherited bilirubin disease or disorder, including not not necessarily limited to Dubin-Johnson Syndrome, Gilbert's syndrome, and Rotor Syndrome

Primary outcomes:
measure: Area Under the Plasma Concentration-time Curve (AUC)
timeFrame: EDP239 P1: D7/15/21: 0 (pre), and postdose 1,2,3,4,5,6,8,12hr P2: at D10 pre and postdose at 1,2,3,4,5,6,8,12hr,D11/12/13/14. DEB025 P1: D15/21 at pre and postdose at 1,2,3,4,5,6,8,12hr P2: D3/10(Per2) at pre, 0.5,1,2,4,6,8,12,24,3,48,72,96,120,144,168
measure: Adverse Events
timeFrame: Part 1: Screening (Day -22 to -2) to Day 35 Part 2: Period 1- Screening (Day -22 to -2) to Day 8 Period 2- Day -1 to 28
measure: Safety Labs
timeFrame: Part 1: Screening (Day -22 to -2), -1, 1, 7, 14, 21 Part 2: Period 1- Screening (Day -22 to -2), Day -1, 8 Period 2- Day -1, 1, 14, 28
measure: Plasma Pharmacokinetics (PK) of DEB025 and EDP239: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)
timeFrame: EDP239 P1: D7/15/21: 0 (pre), and postdose 1,2,3,4,5,6,8,12hr P2: at D10 pre and postdose at 1,2,3,4,5,6,8,12hr,D11/12/13/14. DEB025 P1: D15/21 at pre and postdose at 1,2,3,4,5,6,8,12hr P2: D3/10(Per2) at pre, 0.5,1,2,4,6,8,12,24,3,48,72,96,120,144,168
measure: Vital Signs
timeFrame: Part 1: Screening (Day -22 to -2) to Day 35 Part 2: Period 1- Screening (Day -22 to -2) to Day 8 Period 2- Day -1 to 28
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Investigative Site
Study officials:
affiliation: Enanta Pharmaceuticals, Inc
name: Enanta Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT02196974: Bronchoscopic Approach to the Peripheral Lung Nodule - Endobronchial Ultrasound, Electromagnetic Navigation and Cryobiopsy
Official title: Bronchoscopic Approach to the Peripheral Lung Nodule - Endobronchial Ultrasound, Electromagnetic Navigation and Cryobiopsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Nodules
Keywords: bronchoscopy
lung nodule
diagnosis
cryobiopsy
Lead sponsor: University of Calgary
Sponsor class: OTHER
First posted: 2014-07-22
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: In patients with peripheral lung nodules, what is the additional diagnostic yield of biopsies obtained with flexible cryoprobes compared to standard techniques? For patients with peripheral nodules, we hypothesize use of the cryoprobe will allow larger samples of tissue to be obtained and therefore, will increase the diagnostic yield over conventional techniques


Eligibility criteria: Inclusion Criteria:

* 1. Age \>18 years 2. Lung nodule (s) identified on CT scan 3. Clinical decision to obtain tissue biopsy of lung lesion 4. CT guided biopsy not preferred technique

  * Previous negative CT guided biopsy
  * Technically difficult nodule location
  * Perceived high risk of pneumothorax or other complications

Exclusion Criteria:

* 1. Lack of informed consent 2. Nodule less than 1 cm or greater than 6 cm long axis 3. Significant mediastinal adenopathy. 4. No suspected sites of disease outside the thorax amenable to biopsy 5. Evidence of endobronchial abnormality on chest CT 6. Medical contraindication to bronchoscopy 7. Patients with lesions highly suspicious for lung cancer, potentially resectable with lobar or lesser resection and without significantly increased operative risk factors will not be entered into this study prior to surgical evaluation.

  8. Uncontrolled or irreversible coagulopathy
  * platelets \<100
  * INR \>1.3
  * Use of clopidogrel in the 7 days prior to bronchoscopy 9. Confirmed or suspected pregnancy 10. Clinically unable to tolerate a pneumothorax or single-lung ventilation 11. Pacemaker or implanted cardiac defibrillator if it is felt that ENB is needed

Primary outcomes:
measure: incremental diagnostic yield of cryobiopsy over the standard specimens
timeFrame: 1 year after completion of recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
Study officials:
References:
Clinical trial NCT01682174: Glycaemic Response to a Liquid Meal Tolerance Test
Official title: Effects of Dehydrated Vegetable Powder on Glycaemic Responses to a Liquid Meal Tolerance Test (LMTT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glycaemic Index
Glycaemic Response
Lead sponsor: Mondelēz International, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Reading Scientific Services Ltd.
First posted: 2012-09-10
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to assess whether added food ingredient(s) affect glycaemic responses to a liquid meal tolerance test (LMTT).


Eligibility criteria: Inclusion Criteria:

1. Male or female (not less than 40% Male)
2. Aged 18 - 55 years
3. Non Smokers
4. Have a body mass index between 18.5 to 29.99 kg/m2
5. Healthy, non-diabetic, no gastric bypass surgery
6. Not allergic to dairy, or soy
7. Have a fasting plasma glucose (finger-stick) \<100 mg/dl (\<5.5 mmol/L)
8. Willing and able to provide written informed consent

Primary outcomes:
measure: Glycaemic response (incremental area under the curve) of experimental test food using capillary blood
timeFrame: 120 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Reading
country: United Kingdom
facility: Reading Scientific Services Limited (RSSL)
state: Berkshire
Study officials:
affiliation: RSSL
name: Rungano Munyuki
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02154074: Dexmedetomidine Influence on the Level of Perioperative Blood Glucose and Insulin of Elderly Diabetes Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Perioperative Blood Glucose and Insulin
Keywords: Dexmedetomidine perioperative blood glucose and insulin
Lead sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
Sponsor class: OTHER
First posted: 2014-06-03
Enrollment: 92
Sex: ALL
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dexmedetomidine is a kind of high selectivity alpha 2 agonists adrenaline, can inhibit the activity of sympathetic nerve, alleviate pain,and improve cardiovascular stability in the operation period. Dexmedetomidine have influence on perioperative stress response and immune function,but it is not clear.


Eligibility criteria: Inclusion Criteria:

* Aged 60 to 80 years old;
* Type 2 diabetes;
* Not use insulin treatment;
* Onging general anesthesia surgery;
* Surgery time 1-3 hours

Exclusion Criteria:

* ASA classification \> class II;
* Hypertension;
* Serious central nervous system diseases (acute stroke, uncontrolled seizures, -Severe dementia);
* Unstable angina and acute myocardial infarction;
* Allergy to investigational drug;
* Hepatic and renal dysfunction

Primary outcomes:
measure: blood glucose
timeFrame: from the day before surgery to 24 hours after surgery
measure: level of blood insulin
timeFrame: from the day before surgery to 24 hours after surgery
Secondary outcomes:
measure: vital signs
timeFrame: duration of perioperative period
Other outcomes:
Locations:
city: Xi'an
country: China
facility: SecondXianJiaotongU
state: Shanxi
Study officials:
References:
Clinical trial NCT06207474: A Study on BReast Cancer Patient Care Using chAtbot and Video Education for Radiation Therapy (BRAVE)
Official title: A Study on BReast Cancer Patient Care Using chAtbot and Video Education for Radiation Therapy (BRAVE)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Neoplasms
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2024-01-17
Enrollment: 148
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This randomized trial explored whether digital media (videos and chatbots) used for patient education could more effectively reduce anxiety in breast cancer patients during radiation therapy, compared to traditional paper-based methods. Post-surgery breast cancer patients scheduled for radiation therapy were assigned to groups receiving treatment information through different media combinations. The study aimed to assess whether these modern tools more effectively ease anxiety, thus potentially improving patient compliance and treatment experience.

Detailed description: This study evaluates the impact of patient management and information provision using educational videos and chatbots on patient experience, satisfaction, and patient psychology in the breast cancer radiation treatment process.

The experiment is designed as (2 (with or without using chatbot) X 2 (with or without using video) to distinguish groups.

There is no separate treatment intervention in addition to use chatbot and video utilization.

Eligibility criteria: Inclusion Criteria:

1. A breast cancer patient scheduled for radiation therapy after radical surgery.
2. Subjects must have the cognitive ability to use smartphone.
3. Age ≥ 20 year old

Exclusion Criteria:

1. Patients with visual or auditory impairment.
2. Subjects do not consent to participate in this study.
3. Pregnancy, fetus, newborn, underage
4. Age ≥ 75 year old

Primary outcomes:
measure: APAIS(Amsterdam Preoperative Anxiety and Information Scale)
timeFrame: baseline, before radiation therapy, after all radiation, an average of 1 month
Secondary outcomes:
measure: STAI-X(State-Trait Anxiety Inventory for Adults)
timeFrame: baseline, before radiation therapy, after all radiation, an average of 1 month
measure: LASA(Linear Analog Scale Assessments)
timeFrame: baseline, before radiation therapy, after all radiation, an average of 1 month
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei Cancer Center
Study officials:
affiliation: Yonsei Cancer Center
name: Yong Bae Kim
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01686074: Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
Official title: Motor Control in Chronic Fatigue Syndrome and Fibromyalgia.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fibromyalgia
Chronic Fatigue Syndrome
Keywords: Motor control
walking
physical activity
Muscle activity
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
First posted: 2012-09-17
Enrollment: 90
Sex: ALL
Minimum age (years): 19
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with chronic fatigue syndrome and fibromyalgia from primary care clinics.

Brief summary: This project is a comprehensive study, with main focus on motor control, comparing patients with chronic fatigue syndrome / myalgic encephalopathy (CFS/ME) and/or fibromyalgia syndrome (FMS). Focus of the present project will be on detailed movement analysis in a movement laboratory and involve functional tasks such as walking and standing. Investigations will also comprise muscle activity, reaction time and fine motor control.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of chronic fatigue syndrome or fibromyalgia

Exclusion Criteria:

* patients who already had been treated.

Primary outcomes:
measure: motor control
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Avdeling for smerte og sammensatte symptomlidelser (ASSL) St Olavs Hospital
Study officials:
affiliation: Norwegian University of Science and Technology
name: Egil A Fors, MD prof
role: STUDY_DIRECTOR
References:
citation: Rasouli O, Stensdotter AK, Van der Meer ALH. TauG-guidance of dynamic balance control during gait initiation in patients with chronic fatigue syndrome and fibromyalgia. Clin Biomech (Bristol). 2016 Aug;37:147-152. doi: 10.1016/j.clinbiomech.2016.07.008. Epub 2016 Jul 22.
citation: Rasouli O, Fors EA, Borchgrevink PC, Ohberg F, Stensdotter AK. Gross and fine motor function in fibromyalgia and chronic fatigue syndrome. J Pain Res. 2017 Feb 7;10:303-309. doi: 10.2147/JPR.S127038. eCollection 2017.
Clinical trial NCT00006274: Study of Energy Requirements in Critically Ill Newborns
Official title: Study of Energy Requirements in Critically Ill Newborns
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Respiratory Distress Syndrome
Keywords: cardiovascular and respiratory diseases
neonatal disorders
rare disease
respiratory distress syndrome
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
Collaborators: name: Indiana University School of Medicine
First posted: 2000-09-12
Enrollment: 60
Sex: ALL
Minimum age (years): 24
Maximum age (years): 120
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: NATURAL_HISTORY

Brief summary: OBJECTIVES:

I. Determine the total energy expenditure in term and preterm infants in both well and ill states using the doubly labeled water method.

Detailed description: PROTOCOL OUTLINE: Patients are assigned to one of three groups according to gestational age (24-28 weeks estimated gestational age (EGA) vs 29-34 weeks EGA vs 35 weeks EGA and over) and severity of respiratory illness (need for high frequency ventilation vs stable conventional ventilator settings or extubated within past 24 hours vs no need for mechanical ventilation).

Patients receive water labeled with deuterium and oxygen O 18 by mouth or by gastrostomy tube on days 1 and 7. Urine samples are collected prior to the first dose, 4-6 hours after the first dose, and then every 24 hours until the second dose. All urine is collected for 4-6 hours after the second dose. Samples are analyzed by dual inlet isotope ratio mass spectrometry.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Infants with estimated gestational age (EGA) of at least 24 weeks with respiratory illness who are on high frequency ventilation (HFOV) and meet the following conditions: Appropriate size for gestational age (AGA) No congenital anomalies No medical complications, including seizures and necrotizing enterocolitis

OR

Control infants with EGA of at least 24 weeks Must meet 1 of the following conditions: Requirement for stable conventional ventilator settings with respiratory index score of less than 2.5 and/or extubated within past 24 hours No requirement for mechanical ventilation Must meet all of the following conditions: AGA No congenital anomalies No medical complications, including seizures and necrotizing enterocolitis No documented sepsis by positive blood culture No supplemental oxygen use (infants 35 weeks EGA and over only)

--Prior/Concurrent Therapy--

HFOV group: Concurrent surfactant, theophylline, or inotrope (vasopressor) therapy allowed

Control group: No concurrent inotrope (vasopressor) therapy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Indiana University
state: Indiana
Study officials:
affiliation: Indiana University
name: Catherine A. Leitch
role: STUDY_CHAIR
References:
Clinical trial NCT06113874: The Influence of Desensitizing Agent on Postoperative Sensitivity in Posterior Composite Restoration
Official title: The Influence of Desensitizing Agent on Postoperative Sensitivity in Posterior Composite Restoration: A Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dentin Hypersensitivity
Lead sponsor: University of Alexandria
Sponsor class: OTHER
First posted: 2023-11-02
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the influence of desensitizing agents on reducing post-operative sensitivity in posterior composite.


Eligibility criteria: Inclusion Criteria:

* Patients having active primary class I carious lesions on vital molar teeth either in the middle or the inner third of dentin in the three quadrants of each patients.
* Teeth having a positive reaction to vitality test (cold test), no signs of pulp inflammation, or spontaneous pain before treatment.
* Preoperative radiographic record of the carious lesions.
* Buccolingual width is no more than half the inter-cuspal distance

Exclusion Criteria:

* Excessive tooth wear due to clenching or abnormal habits.
* Patients with direct occlusal contact by antagonist cusp (traumatic occlusion).
* Patients with periodontal or gingival disease.
* Patients using analgesics and/or anti-inflammatory medicine.

Primary outcomes:
measure: Hypersensitivity assessment
timeFrame: up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Faculty of Dentistry, Alexandria University
Study officials:
affiliation: Alexandria University
name: Nessrin Magdy, BDS
role: PRINCIPAL_INVESTIGATOR
affiliation: Alexandria University
name: Waleed El-Mahy, PhD
role: STUDY_DIRECTOR
affiliation: Alexandria University
name: Rania R Afifi, PhD
role: STUDY_CHAIR
References: